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internally and externally validated, the deterministic and probabilistic sensitivity 
analyses were performed to evaluate uncertainty. A base-case analysis was per-
formed for the population of real surgical candidates in both countries. Cost data 
are presented in 2012 euros. Results: In Germany, in the base-case analysis over 
10 years bariatric surgery led to incremental cost of € 2,909 and generated additional 
0.03 years of life and 1.2 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,457/QALY. Over lifetime, surgery led to savings of € 8,522, 
and generated additional 0.7 years of life, and 3.2 QALYs. In France, in the base-case 
analysis over 10 years bariatric surgery led to incremental cost of € 1,106 and gener-
ated additional 1.3 QALYs with incremental cost-effectiveness ratio of € 852/QALY. 
Over lifetime surgery lead to savings of € 8,359, additional 0.5 life years, and 3.4 
QALYs. In both countries surgery was also associated with reduction of incidence 
of diabetes and cardiovascular disorders. One- to three-year delay in provision of 
surgery led to reduction of clinical effectiveness, but had diverse impact on total cost 
in different patient cohorts. ConClusions: In a comprehensive decision analytic 
model, a current mix of surgical methods for bariatric surgery was cost-effective 
at 10 years and cost saving over the lifetime time horizon in Germany and France.
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objeCtives: Obesity is on the rise globally, especially in developed countries and 
Australia is no exception. Currently, the most effective treatment for sustainable 
weight loss is bariatric surgery. This study is the first of its kind to assess the 
cost-effectiveness of 3 bariatric surgery procedures in comparison with standard 
care in Australia. Methods: A decision analytic model incorporating Markov 
process will be undertaken to compare adjustable gastric banding (AGB), Roux-
en-Y Bypass (RYGB) and sleeve gastrectomy (SG) against standard care. The states 
will be based on BMI categories obtained from WHO and NICE guidelines. The 
cycle length will be one year and, owing to the limited availability of long-term 
data for bariatric procedures, the model will have a time horizon of 10 years. 
Utilities will be based on the SF-6D and transition probabilities will be derived 
from a network meta-analysis of BMI reductions as the treatment effect for the 
various comparators. Cost data will be obtained from the Australian Institute 
of Health and Welfare (AIHW). Construction of the model will be carried out via 
Microsoft Excel and the results will be presented as a comparison of costs and 
quality-adjusted-life years (QALYs) to generate ICERs for each of the interven-
tions. One-way sensitivity analysis in addition to PSA will be carried out to test 
the robustness of the model in terms of the assumptions made and various input 
parameters. Results: Construction of the model has already commenced and 
will be finished by mid-July; full completion of the write-up will be completed by 
the end of July. This research is carried out in conjunction between City University 
London and Griffiths University (Brisbane, Australia). ConClusions: To be com-
pleted by 15/07/2015.
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objeCtives: Haemophilia A causes a considerable burden on society. While prophy-
laxis in children aged ≤ 2y is now a gold standard treatment, the benefits of late 
secondary prophylaxis are still controversial. Aim of this study is to estimate the 
cost-utility of antihemophilic factor rFVIII-FS (Kogenate® FS) in secondary prophy-
laxis vs on-demand regimen from the Italian healthcare system (NHS) and society 
perspective. Methods: An individual patient simulation model was adapted to 
estimate the costs and outcomes associated with secondary prophylaxis and on-
demand treatment. The model follows a hypothetical cohort of 1000 patients in a 
lifetime period. The POTTER observational study represented the source for clinical 
data such as clothing factors regimens and consumption, adherence to prophylaxis, 
risk of joint and total bleeds, quality-of-life (QOL) scores and productivity loss. For 
other data such as intracranial haemorrhage and major surgery rate, data from 
published literature were used. Drugs costs were estimated using prices reimbursed 
by the NHS while hospital costs were estimated with national hospital (inpatient 
and outpatient) tariffs. Caregivers’ or patients’ productivity loss was estimated with 
Italian daily Gross Net Product per-capita. Costs and benefits were discounted at 
6.0% in line with published economic evaluations on this subject. Incremental 
cost-effectiveness ratios (ICERs) were calculated. Model outcomes are expressed 
in terms of costs per quality-adjusted-life-years (QALY). Results: As expected, 
mean lifetime costs are higher with secondary prophylaxis than with on-demand 
treatment. Secondary prophylaxis however determines better outcomes in bleed-
ing reduction and better QoL. Using the NHS perspective (considering only direct 
healthcare costs) secondary prophylaxis shows an ICER vs on-demand of € 51,202/
QALY; a more favourable ICER of € 45,432/QALY is shown when considering also indi-
rect costs. ConClusions: Despite the high cost of the pharmacological treatment, 
antihemophilic factor rFVIII-FS in secondary prophylaxis represents a cost-effective 
approach compared with on-demand treatment.
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generated additional 1.5 QALYs with incremental cost-effectiveness ratio of € 1,405 
per QALY. Over lifetime surgery lead to savings of € 5,032, additional 0.8 life years, 
and 4.1 QALYs. In Italy, in the base-case analysis over 10 years bariatric surgery led 
to incremental cost of € 2,552 and generated additional 1.1 QALYs with incremen-
tal cost-effectiveness ratio of € 2,314/QALY. Over lifetime, surgery led to savings of 
€ 8,874, and generated additional 0.5 years of life, and 3.2 QALYs. ConClusions: 
In a comprehensive decision analytic model, a current mix of surgical methods for 
bariatric surgery was cost-effective at 10 years and cost saving over the lifetime 
time horizon in three European countries.
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objeCtives: Controversy surrounds the most appropriate initial treatment regimen 
for Rheumatoid Arthritis. The objective of the present study is to aid in this debate 
by providing cost-effectiveness and cost-utility analyses for four treatment scenar-
ios. Methods: Estimates of costs were applied to outcome data from the Treatment 
of Early Aggressive Rheumatoid Arthritis (TEAR) Trial to determine cost-effective-
ness. Treatment regimens from the TEAR trial, immediate etanercept (IE), immediate 
triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) (IT), step-up 
etanercept (SE), and step-up triple therapy (ST), were compared. Each regimen used 
methotrexate as a background medication. Outcomes analyzed include Disease 
Activity Scores (DAS-28-ESR) from the TEAR trial, calculated Clinical Disease Activity 
Index (CDAI) scores, and Quality-adjusted Life Years (QALYs) calculated using lit-
erature estimates. Discontinuers were assigned cost and outcome estimates based 
on duration of participation and associated outcomes. Analysis was limited to the 
two year time horizon of the TEAR trial. Results: ST was cost-effective for all 
outcome measures, and had the highest net monetary benefit (NMB) for DAS-28-
ESR ($592,569) and QALYs ($71,080), using a willingness to pay (WTP) of $250,000. 
IE was dominated for CDAI and had the lowest NMBs for DAS-28-ESR and QALYs, 
with incremental cost-effectiveness ratios (ICERs) of $1,025,534 and $8,205,670, 
respectively. SE was dominated for all outcomes. Results from one-way and proba-
bilistic sensitivity analysis were consistent with these findings. ConClusions: 
The treatment strategies using etanercept were more costly than triple therapy 
strategies, with similar outcomes and ICERs outside most acceptable levels. SE was 
not cost-effective for any outcome, and ST was a consistently cost-effective treat-
ment strategy.
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objeCtives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease, affecting 
0.68% of adult population in Greece. RA is associated with decreased quality of life 
and a significant economic burden. The intravenous (IV) formulation of Tocilizumab 
(TCZ) has already proven its efficiency and thus the aim of this study is to evaluate 
and confirm the cost-effectiveness of the subcutaneous (SC) formulation as first line 
biologic monotherapy. Methods: Lifetime costs and outcomes for 10,000 patients 
were projected through an individual simulation model. The analysis compared a 
standard treatment pathway (STP) (Adalimumab, Etanercept and Palliative care) with 
a similar pathway where treatment was initiated with TCZ SC. Health Assessment 
Questionnaire (HAQ) scores were used to reflect disease severity. The primary efficacy 
outcome considered was American College of Rheumatology (ACR) response. Patient 
baseline characteristics derived from the ADACTA trial. Efficacy data were elicited 
from a network meta-analysis. A mapping model transformed HAQ scores into QALYs. 
Clinical practice standards were determined by Expert Opinion (12 Rheumatologists). 
Costs for pharmaceuticals and unit costs for resources were obtained from official 
price lists. Estimated mandatory rebates for new products were taken into account. 
A third-party payer (Social Insurance) perspective was employed. Costs and QALYs 
were discounted at 3%. Results: The treatment sequence starting with TCZ SC 
yielded 0.98 more QALYs (9.08vs. 8.10) at an additional cost of € 27,442.5 (€ 132,733.78 
vs. € 105,291.27) compared to the STP.The Incremental Cost – Effectiveness Ratio (ICER) 
was estimated at € 27,974.28 per QALY gained which is below the national commonly 
used threshold. Probabilistic Sensitivity Analysis confirms robustness of findings 
below a threshold of € 45,000. ConClusions: The results of the analysis suggest that 
TCZ SC can be a cost-effective alternative and provide both patients and health care 
system with more options for RA management due to dual formulation’s effective-
ness and efficiency.
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objeCtives: To evaluate the cost-utility of bariatric surgery in Germany and France 
from a third-party payer perspective over a mid-term (10 years) and a long-term (life-
time) horizon. Methods: A state-transition Markov model was developed, in which 
patients may experience surgery, post-surgery complications, diabetes mellitus type 
2, cardiovascular diseases or die. Transition probabilities, data about effectiveness 
and safety of surgery, costs, and utilities were informed by the literature, patient 
registries and administrative databases. Three types of surgeries were considered: 
gastric bypass, sleeve gastrectomy, and adjustable gastric banding. The model was 
A672  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PSY78
inPatiEnt BurdEn among PatiEntS With CYStiC fiBroSiS Who arE 
homozYgouS for thE f508dEl mutation
Hodgkins P1, Ayyagari R2, Guo J2, Wagener J3, O’Sullivan AK1
1Vertex Pharmaceuticals, Boston, MA, USA, 2Analysis Group, Inc, Boston, MA, USA, 3University of 
Colorado, Aurora, CO, USA
objeCtives: To examine inpatient utilization among patients with cystic fibrosis 
(CF) and homozygous for the F508del CFTR gene mutation. Methods: Medical 
chart data from patients with CF ≥ 12 years old were collected in France, Germany, 
Italy, Spain, Australia and Canada. Demographics and clinical characteristics were 
obtained for a 12-month baseline period and a follow-up period ranging from 2-36 
months. Proportions of patients hospitalized, hospitalization rates, and length of 
stay were assessed overall and by age (12-17, ≥ 18 years), lung function (percent 
predicted forced expiratory volume in 1 second [ppFEV1] ≥ 70%, 41-69%, ≤ 40%), and 
country. Results: Data for 523 patients were included. Baseline mean ± SD age was 
24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%. Over a mean of 27 months 
follow-up, 19% of patients had 1 hospitalization, 11% had 2, and 37% had ≥ 3. The 
mean ± SD rate of hospitalizations was 1.2 ± 1.5 per patient-year. In the follow-up 
period, the proportion of patients with at least 1 hospitalization and the rate of 
hospitalization were highest for the severe ppFEV1 group relative to moderate and 
mild groups (86%, 73%, and 55% and 2.1 ± 2.0, 1.4 ± 1.6 and 0.7 ± 1.1 per patient-year 
respectively). The overall mean length of stay was 10.7 ± 7.5 days; it was 9.2 ± 6.8 days 
for the mild lung function group vs 11.0 ± 6.7 days for the severe group. The hospi-
talization rate ranged from 0.6 ± 1.1 per patient-year in Spain to 1.7 ± 1.9 in Australia; 
trends by lung function were consistent across countries. ConClusions: Patients 
with CF and homozygous for the F508del CFTR gene mutation have high rates of 
hospitalization. Hospitalization rate varies by country, but is consistently higher 
for patients with the lowest lung function, congruent with a progressive disease.
SYStEmiC diSordErS/ConditionS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. The pur-
pose of this study was to assess the health-related quality of life (HRQoL) impair-
ment of TTR-FAP disease versus Portuguese general population. Literature on 
TTR-FAP patients HRQoL is scarce at worldwide level and no evidence on HRQoL 
index score for Portugal has been published. Methods: HRQoL was measured using 
the validated EuroQoL five dimensions three levels (EQ5D-3L) questionnaire being 
the index score (utility) calculated trough the Portuguese scoring algorithm. The 
Portuguese general population reference set (n = 1500) was pooled with TTR-FAP 
patients specific data (n = 1091) extracted from Transthyretin Amyloidosis Outcomes 
Survey (THAOS) registry. Demographic variables include gender and age. Ordinary 
Least Squares (OLS) regression for utility was set to test if being asymptomatic 
carrier caused HRQoL impairment, conditional in other individual characteristics. 
Generalized linear models (GLM) were specified for disutility in order to disentan-
gle and quantify TTR-FAP effect on HRQoL versus Portuguese general population. 
Akaike information criteria (AIC) were used to select the most adequate statistical 
model. Results: In a scale from -0.50 to 1.00 the average utility score was 0.76 (0.25) 
for general population, 0.823 (0.24) for TTR-FAP asymptomatic carriers (n= 525) and 
0.50(0.37) for symptomatic TTR-FAP patients (n= 566). OLS including independent 
gender and age variables, indicated no significant statistical effect on utility for 
being a TTR-FAP asymptomatic carrier (p-value 0.54) versus general population. 
GLM (AIC -0.58) detected a significant statistical effect for gender, age and being 
symptomatic TTR-FAP patient. Average women aged 44 years and symptomatic 
TTR-FAP patient, has a 40% impairment on utility versus women aged 44 years from 
general population. ConClusions: The preference-based utility measures used 
in this study adequately disentangle TTR-FAP disease impact on patient’s health-
related quality of life. This study allows us to quantify the large HRQoL effect that 
TTR-FAP induces.
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objeCtives: Economic evaluations of Gaucher disease type 1 (GD1) performed to 
date have used utilities for narrowly defined GD1 health states derived from spe-
cific patient populations. The aim of this study was to calculate alternative utilities 
for GD1 health states based on a standard disease severity measure. Methods: 
Health states were based on components of the Disease Severity Scoring System 
(DS3), a validated measure capturing hematologic, visceral, and bone domains of 
GD1. Nine states were defined using combinations of DS3 severity categories (mild, 
moderate, marked, and severe) and the presence or absence of bone pain (BP) or 
skeletal complications (SSC): mild, mild+BP, mild+SSC, moderate, moderate+SSC, 
marked, marked+SSC, severe, and severe+SSC. DS3 and quality of life (SF-36) data 
came from a sample of GD1 patients enrolled in the ICGG Gaucher Registry (275 
observations, 101 patients). SF-36 data were converted to UK EQ-5D utilities using 
published methods. We fitted a generalized estimating equation, accounting for 
multiple observations per patient, containing terms for DS3 severity categories, BP, 
objeCtives: The objective of this study was to assess the cost-effectiveness and 
cost-utility of dasatinib versus FLAM (fludarabine, cytarabine, mitoxantrone) chemo-
therapy in treatment of adult patients with Ph+ ALL with resistance or intolerance 
to prior therapy from the public payer’s perspective in Poland. Methods: The 
constructed Markov model compared the costs and health effects of dasatinib and 
FLAM treatment for the average patient in the life-time horizon. The model included 
the following health states: survival without progression, survival after allogeneic 
hematopoietic stem cell transplantation (allo-HSCT), survival after progression 
and death. Data on clinical effectiveness of dasatinib and FLAM were retrieved 
from single-arm clinical trials, whereas data for overall survival after allo-HSCT 
and after progression was taken from long-term studies. The utilities for all health 
states were identified by systematic review. The following costs from public payer’s 
perspective were considered: substances and their administration (chemotherapy), 
monitoring, allo-HSCT, monitoring and chemotherapy after allo-HSCT and palliative 
care. Discount rates of 5% for costs and 3.5% for benefits were used. Results: The 
amount of life years gained associated with dasatinib arm and FLAM arm in the 
life-time horizon was 1.79 LYG and 1.17 LYG, respectively. Treatment with dasatinib 
resulted in 1.48 QALY and with FLAM – 0.94 QALY. The incremental cost-effective-
ness ratio (ICER) of dasatinib versus FLAM was estimated to be € 24,145/LYG from the 
perspective of Polish National Health Fund and it is below the threshold accepted 
for Poland (€ 27,275/QALY). The result of cost-utility analysis are almost equal to the 
threshold accepted for Poland and amount to € 28,146/QALY. ConClusions: Taking 
into account the status ALL as ultra-rare disease and the results of economic evalua-
tion, dasatinib is the cost-effective strategy in comparison with FLAM chemotherapy 
in treatment Ph+ ALL patients with resistance or intolerance to prior therapy from 
the public payer’s perspective in Poland.
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objeCtives: The introduction of complementary foods around the age of six month 
is necessary as infant’s need for energy and nutrients starts to exceed what is 
provided by breast milk. One of the key nutrients that infant’s demand could not 
be met only by partial breastfeeding is iron. The objective of this study is to shed 
some light on the role of complementary foods on the iron status of children using 
the food categories reported in the Indian National Family Health Survey 2005-06 
(NFHS-3). Methods: The analysis presents the results of three set of regressions 
to associate hemoglobin / anemia levels and 17 feeding categories controlling for 
cofounders. First, ordinary least square (OLS) regressions on the hemoglobin level 
shown. Second, logistic regressions were used to estimate the odd ratio of becoming 
anemic and moderate or severe anemic. Finally, with proportional odds (ordered 
logit) model it was estimated the risk from passing to one to other category in 
anemia. Results: “Commercial fortified baby food” together with “partial breast-
feeding” and “infant formula” having the stronger positive and statistical significant 
association with iron status for infants aged six to 23 months. Additionally, “fruits 
rich in vitamin A” and “meat and fish” have also a significantly positive association 
with iron status. On the contrary, “tea or coffee”, “no commercial porridge” and 
“bread or noodles” categories tend to have a significant negative association with 
iron measurement. ConClusions: Infants in India are introduced relatively late to 
iron rich foods which would allow them to replenish their iron stores from birth at 
the appropriate moment. Infant nutritional guidelines should emphasis the benefits 
of fortified baby food as well as a variety of food that would enhance the iron status 
on this highly vulnerable age group.
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objeCtives: Understanding resource use in multiple myeloma (MM) is important 
for assessing the value of new treatments. This study investigated unplanned 
hospitalisations and factors associated with increased incidence of hospitalisa-
tion in patients with MM. Methods: Primary care data from the UK Clinical 
Practice Research Datalink and Hospital Episode Statistics were collected during 
1 January–31 December 2010 for adults who were alive and already diagnosed 
with MM on 1 January 2010. The primary outcome, unplanned hospitalisation, 
was defined as an emergency admission involving an overnight stay. Patient and 
disease characteristics were reported according to hospitalisation status and num-
ber of hospitalisations. Results: At baseline, median age of the 769 patients was 
72 years and median time since diagnosis was 3.1 years. 31.6% of patients had at 
least one unplanned hospitalisation; of these, 43.2% were rehospitalised during the 
study period. Patients with unplanned hospitalisations were older (median 74 vs 
71 years) and more likely to have renal failure (43.6% vs 31.2%) or cardiac disease 
(40.3% vs 29.1%) than those without hospitalisation (p< 0.005). There were no sig-
nificant differences in the prevalence of diabetes or prior stem cell transplantation. 
Admissions were most frequently to general medicine (35.7%) or haematology 
(19.8%) departments. Excluding MM, hospitalisations were most commonly for 
acute lower respiratory infection (6.6%) and lobar pneumonia (5.4%). Stays were 
longer for patients with at least two unplanned hospitalisations than for those 
with one (mean 12 vs 10 days; p= 0.0761). ConClusions: Renal failure and cardiac 
disease (common among elderly MM patients) were significantly associated with 
unplanned hospitalisations. Admissions were often lengthy and required treat-
ment in specialist units (e.g. haematology departments). Such hospitalisations 
are likely to incur high costs. The results indicate an unmet need in MM manage-
ment to more successfully control the burden of the disease and thereby reduce 
associated resource utilisation.
